Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ELI-002 |
| Trade Name | |
| Synonyms | ELI002|ELI 002 |
| Drug Descriptions |
ELI-002 is a peptide-based cancer vaccine consisting of KRAS G12D and G12R peptides with an adjuvant Amph-modified CpG oligonucleotide, which potentially increases antitumor immune response (PMID: 38195752). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C179231 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ELI-002 | ELI-002 | 0 | 2 |